Biological E gets WHO nod to be additional facility for production of Johnson & Johnson Covid vaccine
- Country:
- India
Biological E has received the WHO nod to be an additional facility for production of Johnson & Johnson COVID-19 vaccine.
''Congratulations to @biological_e on its @WHO approval as an additional manufacturing site for the Janssen/Johnson & Johnson COVID-19 vaccine! Great progress for the Quad Vaccine and #USIndiaHealth partnerships through U.S. technical support and @DFCgov financing,'' the US embassy in India said in a tweet on Wednesday.
India's first indigenously developed RBD protein subunit vaccine, Biological E's Corbevax, is currently being used to inoculate children in the age group of 12 to 14 years.
The Drugs Controller General of India (DCGI) recently approved Corbevax as a precaution dose for those aged 18 and above.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
ALSO READ
Indian talent in IT sector will play important role in bringing jobs to India: Anurag Thakur
Indian-origin Singaporean minister emphasises importance of introducing children to Tamil language
Indian child sex offender arrested after Maryland courts give light sentences: ICE
'No ground' for Indian request for return of Kachchatheevu: Lanka Minister
India continues to be largest recipient of remittances, says RBI Governor Shaktikanta Das.